{"id":325,"date":"2025-09-17T05:50:21","date_gmt":"2025-09-17T05:50:21","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=325"},"modified":"2025-09-17T13:59:12","modified_gmt":"2025-09-17T13:59:12","slug":"china-nmpa-approved-new-drugs-non-small-molecules","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/325.html","title":{"rendered":"China NMPA Approved New Drugs (Biological Products)"},"content":{"rendered":"\n
Target<\/td>Drug Name<\/td>Code<\/td>Approved Time<\/td>Company<\/td>Partner<\/td><\/tr>
PD-1 mAb<\/td>Toripalimab<\/td>JS001<\/td>2018-12<\/td>Junshi<\/td>LO: Coherus<\/td><\/tr>
PD-1 mAb<\/td>Sintilimab<\/td>IBI308<\/td>2018-12<\/td>Innovent<\/td>LO: Eli Lilly<\/td><\/tr>
PD-1 mAb<\/td>Camrelizumab<\/td>SHR-121<\/td>2019-05<\/td>Hengrui<\/td><\/td><\/tr>
PD-1 mAb<\/td>Tislelizumab<\/td><\/td>2019-12<\/td>BeOne<\/td>LO: <\/td><\/tr>
PD-1 mAb<\/td>Penpulimab<\/td>AK105<\/td>2021-08<\/td>Akeso<\/td>CTTQ<\/td><\/tr>
PD-1 mAb<\/td><\/td>HX008<\/td>2022-07<\/td>Lepu<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
PD-L1 mAb<\/td>Adebrelimab<\/td><\/td>2023-02<\/td>Hengrui<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
PD-1\/CTLA-4 BsAb<\/td>Candonilimab<\/td><\/td>2022<\/td>Akeso<\/td><\/td><\/tr>
CD20 mAB<\/td>Zuberitamab<\/td><\/td>2023-05<\/td><\/td><\/td><\/tr>
HER2 ADC<\/td>Disitamab Vedotin<\/td>RC48<\/td>2021-06<\/td>RameGen<\/td>LO: Seagen<\/td><\/tr>
HER2 ADC<\/td>Trastuzumab Rezetecan<\/td>SHR-A1811<\/td>2025-05<\/td>Hengrui<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
TROP2 ADC<\/td>Sacituzumab Tirumotecan<\/td><\/td>2024-11<\/td>Kelun<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
VEGF-A\/PD-1 BsAb<\/td>Ivonescimab<\/td><\/td>2024<\/td>Akeso<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
IL-4R\u03b1<\/td>Stapokibart <\/td><\/td><\/td>Kangnuoxing<\/td><\/td><\/tr>
<\/td><\/td><\/td><\/td><\/td><\/td><\/tr>
IL-17A mAb<\/td>Vunakizumab<\/td><\/td>2025<\/td>Suncadia<\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"

Target Drug Name Code Approved Time Company Partner PD-1 mAb Toripalimab JS001 2018-12 Junshi LO: Coherus … China NMPA Approved New Drugs (Biological Products)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-325","post","type-post","status-publish","format-standard","hentry","category-china-new-drug"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=325"}],"version-history":[{"count":10,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/325\/revisions"}],"predecessor-version":[{"id":352,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/325\/revisions\/352"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}